RP Masiello is building a new manufacturing facility for EyePoint Pharmaceuticals, a company that develops new treatments and drug-delivery systems for challenging eye diseases, including macular degeneration, the leading cause of vision loss among adults. The building is expected to be completed in late 2024. EyePoint Pharmaceuticals will be the sole tenant in the new building.

The 40,000 sq.-ft. building, located on Commerce Drive in Northbridge, MA, will be designed and constructed to meet the rigorous requirements of good manufacturing practices (GMP) and allow EyePoint to meet U.S. FDA and European Medicines Agency (EMA) standards for producing therapeutics.

EyePoint’s new facility will be customized for their specific development and manufacturing programs. It will include pharmaceutical production suites for clinical supply and commercial scale manufacturing of approved products, plus chemistry and development laboratories and manufacturing support spaces, all built to ISO 7 clean room standards. The facility will accommodate quality control and quality assurance (QC/QA) functions and administrative spaces to support continued growth of their global business.

Among the specialized mechanical systems to be installed in the building are an advanced water filtration system to further purify municipal water used in the manufacturing and testing processes; filtration systems and lab fume hoods to maintain interior air quality, and a propane-fired electric generator capable of powering the building for four days in the event of an electrical outage.

“Building to the standards of GMP requires extensive knowledge of the design and operating requirements, plus experience building complex facilities,” said David Masiello, president of RP Masiello. “Working closely with EyePoint and the developer, we have assembled an outstanding design, engineering, commissioning, and construction team that will deliver this important building.”